Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dextroamphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.64 |
| ▸ | PNMT | P11086 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dextroamphetamine SCHEMBL8859 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL1560962 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL13746679 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Levamfetamine SCHEMBL2636 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL13747797 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL4781164 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL910141 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL8858 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL20211418 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL13747801 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008116165-A9 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY INC (US) | 2009-06-11 | — | — | WO | claimed |
| WO-2008116165-A2 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY, INC. (US) | 2008-09-25 | — | — | WO | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| EP-4255541-A1 | PRODUCT DELIVERY DEVICES AND METHODS | Breathe Restore, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022118225-A1 | PRODUCT DELIVERY DEVICES AND METHODS | BREATHE RESTORE, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| US-11333639-B2 | LC-MS configuration for purification and detection of analytes having a broad range of hydrophobicities | COHESIVE TECHNOLOGIES, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20200209203-A1 | LC-MS Configuration for Purification and Detection of Analytes Having a Broad Range of Hydrophobicities | COHESIVE TECHNOLOGIES INC. | 2020-07-02 | — | — | US | disclosed |
| US-10627374-B2 | LC-MS configuration for purification and detection of analytes having a broad range of hydrophobicites | COHESIVE TECHNOLOGIES INC. (US) | 2020-04-21 | — | — | US | disclosed |
| EP-3570036-A1 | LC-MS CONFIGURATION FOR PURIFICATION AND DETECTION OF ANALYTES HAVING A BROAD RANGE OF HYDROPHOBICITIES | Cohesive Technologies Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-2633324-B1 | LC-MS CONFIGURATION FOR PURIFICATION AND DETECTION OF ANALYTES HAVING A BROAD RANGE OF HYDROPHOBICITIES | COHESIVE TECH INC (US) | 2018-11-21 | — | — | EP | disclosed |
| CN-103271083-B | Multi-functional ionic liquid compositions | 阿拉巴马大学 | 2017-08-11 | — | — | CN | disclosed |
| US-20160022659-A1 | METHODS FOR TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A COMBINATION OF BUPROPION ((±)-2-(TERT-BUTYLAMINO)-1-(3-CHLOROPHENYL)PROPAN-1-ONE) AND PHENTERMINE (2-METHYL-1-PHENYLPROPAN-2-AMINE) | WINSTON THOMAS R (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160015642-A1 | CONTROLLED DOSE DRUG DELIVERY SYSTEM | SHIRE LLC (US) | 2016-01-21 | — | — | US | disclosed |
| US-20150080474-A1 | CONTROLLED DOSE DRUG DELIVERY SYSTEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-19 | — | — | US | disclosed |
| EP-2827884-A1 | SILK RESERVOIRS FOR DRUG DELIVERY | Trustees Of Tufts College (US) | 2015-01-28 | — | — | EP | disclosed |
| US-20140047906-A1 | LC-MS CONFIGURATION FOR PURIFICATION AND DETECTION OF ANALYTES HAVING A BROAD RANGE OF HYDROPHOBICITES | COHESIVE TECHNOLOGIES INC. (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2013148158-A1 | LASER-ACTUATED THERAPEUTIC NANOPARTICLES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013142119-A1 | SILK RESERVOIRS FOR DRUG DELIVERY | TRUSTEES OF TUFTS COLLEGE (US) | 2013-09-26 | — | — | WO | disclosed |
| EP-2633324-A1 | LC-MS CONFIGURATION FOR PURIFICATION AND DETECTION OF ANALYTES HAVING A BROAD RANGE OF HYDROPHOBICITIES | Cohesive Technologies Inc. (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012058619-A1 | LC-MS CONFIGURATION FOR PURIFICATION AND DETECTION OF ANALYTES HAVING A BROAD RANGE OF HYDROPHOBICITIES | COHESIVE TECHNOLOGIES INC. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022659-A1 | METHODS FOR TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A COMBINATION OF BUPROPION ((±)-2-(TERT-BUTYLAMINO)-1-(3-CHLOROPHENYL)PROPAN-1-ONE) AND PHENTERMINE (2-METHYL-1-PHENYLPROPAN-2-AMINE) | PNMT, HTR2A, HTR2C | SLC6A2 13/4885SLC6A3 22/4885TAAR1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.